Stocktoria
Cardiff Oncology, Inc. CRDF
Cardiff Oncology, Inc. (CRDF) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $593,000 at a -7732.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CRDF | Cardiff Oncology, Inc. | 2/9 | — | — | — |
| IMA | ImageneBio, Inc. | 3/9 | 5.55 | — | — |
| PROK | PROKIDNEY CORP. | 1/9 | — | — | — |
| ATYR | aTYR PHARMA INC | 1/9 | -19.49 | — | — |
| ZIVO | Zivo Bioscience, Inc. | 4/9 | — | — | — |
| VIVS | VivoSim Labs, INC. | 2/9 | — | — | — |
| INMB | Inmune Bio, Inc. | 3/9 | — | — | — |
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
FAQ
Is CRDF financially healthy?
Cardiff Oncology, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does CRDF pay a dividend?
No, Cardiff Oncology, Inc. does not currently pay a dividend.
How profitable is CRDF?
In FY2025, Cardiff Oncology, Inc. had a net margin of -7732.0% and a return on equity of -101.0%.
What is the analyst price target for CRDF?
The average Wall-Street price target for Cardiff Oncology, Inc. is $5.21, about 426.4% above the recent price, from 7 analysts (consensus: buy).
Is CRDF a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cardiff Oncology, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.